Last update
3/10/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
USERS' SCORE
Good
Based on 25 Reviews
8.1
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2(as Menaquinone-7) (MK-7 ) (MenaQ7®)
100 mcg
**
Top Medical Research Studies
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
Most Useful Reviews
9
Artery calcification reduction
8 people found this helpful
I've used Now Foods MK-7 for 2 years. At 73, my heart condition remains good as it helps remove artery calcification. My nails have changed from brittle to strong, and my hair has become thicker.
Read More
9
Regular heartbeat noted
7 people found this helpful
After taking K2, LactoBif 30, and ubiquinol for nearly six months, my irregular heartbeat has improved remarkably. Although I’m unsure which supplement made the difference, I believe these quality ingredients have significantly enhanced my heart health.
Read More
7.5
Confident quality assurance
6 people found this helpful
This is my second purchase, and I'm always satisfied. The quality aids in maintaining my heart health and lupus management. Vitamin D and K2 work well together. The product arrived quickly in good condition, and I trust its authenticity.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
- All Researches
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
User Reviews
USERS' SCORE
Good
Based on 25 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
9
Artery calcification reduction
8 people found this helpful
I've used Now Foods MK-7 for 2 years. At 73, my heart condition remains good as it helps remove artery calcification. My nails have changed from brittle to strong, and my hair has become thicker.
Read More
9
Regular heartbeat noted
7 people found this helpful
After taking K2, LactoBif 30, and ubiquinol for nearly six months, my irregular heartbeat has improved remarkably. Although I’m unsure which supplement made the difference, I believe these quality ingredients have significantly enhanced my heart health.
Read More
7.5
Confident quality assurance
6 people found this helpful
This is my second purchase, and I'm always satisfied. The quality aids in maintaining my heart health and lupus management. Vitamin D and K2 work well together. The product arrived quickly in good condition, and I trust its authenticity.
Read More
7.5
Supports heart health
5 people found this helpful
Since taking this product, calcium deposits on my heart valves have been reduced, leading to a more stable heart.
Read More
7.5
Promotes heart health
2 people found this helpful
I’m purchasing this for myself and my parents, as K2 is beneficial for D3 absorption and artery decalcification. I hope none of us will suffer from heart disease. I trust the quality of Now supplements, including this one. The size is reasonable, and the dosage aligns with daily limits for those without serious calcification issues. MK-7 is the best-absorbed version of K2.
Read More
Frequently Asked Questions
9
Regular heartbeat noted
7 people found this helpful
After taking K2, LactoBif 30, and ubiquinol for nearly six months, my irregular heartbeat has improved remarkably. Although I’m unsure which supplement made the difference, I believe these quality ingredients have significantly enhanced my heart health.
9
Artery calcification reduction
8 people found this helpful
I've used Now Foods MK-7 for 2 years. At 73, my heart condition remains good as it helps remove artery calcification. My nails have changed from brittle to strong, and my hair has become thicker.
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
4
We examined the effectiveness and safety of anti-thrombotic therapy after surgical mitral valve repair (MVr). Our scoping review analyzed 11 studies, including randomized controlled trials and cohort studies, which assessed various therapies like vitamin K antagonists. The results were inconsistent, showing that some therapies had no significant difference in reducing thromboembolic events, while bleeding rates varied widely. Due to design limitations in existing literature, we highlighted the need for a well-structured future study to provide clearer guidance on anti-thrombotic management in MVr patients.
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
References
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. 10.1161/JAHA.124.038834
- Babadagli HE, Ye J, Chen J, Turgeon R, Wang EH. Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review. Open Heart. 2025;12. 10.1136/openhrt-2024-003158
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
- Macias-Cervantes HE, Ocampo-Apolonio MA, Guardado-Mendoza R, Baron-Manzo M, Pereyra-Nobara TA, et al. Effect of vitamin K1 supplementation on coronary calcifications in hemodialysis patients: a randomized controlled trial. J Nephrol. 2025;38:511. 10.1007/s40620-024-02154-9
- Preda A, Falasconi G, Melillo F, Margonato D, Posteraro GA, et al. Left atrial appendage closure in patients with failure of anticoagulation therapy: A multicenter comparative study on the hybrid strategy using DOACs and VKAs. Int J Cardiol. 2025;421:132875. 10.1016/j.ijcard.2024.132875
Data last updated:
